About MPCs, an Investigational Regenerative Medicine
evaluated as an investigational regenerative medicine for patients with advanced chronic heart failure (CHF)
MPCs, an Investigational
The DREAM HF-1 clinical trial is a study of a type of investigational regenerative medicine which consists of Mesenchymal Precursor Cells (or MPCs). According to the U.S. Food & Drug Administration’s 21st Century Cures Act, regenerative medicine therapies are defined as “cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products”.
The MPCs used in DREAM HF-1 are produced from cells obtained from the bone marrow of a healthy, unrelated adult who donated some of their bone marrow. The donor was tested carefully for many diseases to minimize the possibility that a disease would be passed on to any recipient of MPCs in an investigational trial. The cells were isolated from the healthy adult donor’s bone marrow, further purified, grown, further tested and then frozen.
DREAM HF-1 is a trial aimed at evaluating the potential clinical benefits and safety of MPCs in patients with advanced CHF. DREAM HF-1 trial participants are being evaluated to demonstrate that MPCs result in a decrease in heart failure-related hospitalizations, delay or prevention of heart transplantation and/or left ventricular assist device (LVAD) implantation, and decrease in cardiac-related death when administered to patients with advanced chronic heart failure (CHF). MPCs being used in this study are being evaluated for their potential to help your heart work more efficiently by helping to restore heart muscle function as compared with standard-of-care medical therapy.